| 1. |
- Abazov, V. M., et al.
(author)
-
The upgraded DO detector
- 2006
-
In: Nuclear Instruments and Methods in Physics Research Section A. - : Elsevier BV. - 0168-9002 .- 1872-9576. ; 565:2, s. 463-537
-
Journal article (peer-reviewed)abstract
- The DO experiment enjoyed a very successful data-collection run at the Fermilab Tevatron collider between 1992 and 1996. Since then, the detector has been upgraded to take advantage of improvements to the Tevatron and to enhance its physics capabilities. We describe the new elements of the detector, including the silicon microstrip tracker, central fiber tracker, solenoidal magnet, preshower detectors, forward muon detector, and forward proton detector. The uranium/liquid -argon calorimeters and central muon detector, remaining from Run 1, are discussed briefly. We also present the associated electronics, triggering, and data acquisition systems, along with the design and implementation of software specific to DO.
|
|
| 2. |
|
|
| 3. |
- Connolly, S., et al.
(author)
-
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events
- 2006
-
In: American heart journal. - 1097-6744. ; 151:6, s. 1187-93
-
Journal article (peer-reviewed)abstract
- BACKGROUND: Atrial fibrillation (AF) is the most frequently occurring cardiac arrhythmia with often serious clinical consequences. Many patients have contraindications to anticoagulation, and it is often underused in clinical practice. The addition of clopidogrel to aspirin (ASA) has been shown to reduce vascular events in a number of high-risk populations. Irbesartan is an angiotensin receptor-blocking agent that reduces blood pressure and has other vascular protective effects. METHODS AND RESULTS: ACTIVE W is a noninferiority trial of clopidogrel plus ASA versus oral anticoagulation in patients with AF and at least 1 risk factor for stroke. ACTIVE A is a double-blind, placebo-controlled trial of clopidogrel in patients with AF and with at least 1 risk factor for stroke who receive ASA because they have a contraindication for oral anticoagulation or because they are unwilling to take an oral anticoagulant. ACTIVE I is a partial factorial, double-blind, placebo-controlled trial of irbesartan in patients participating in ACTIVE A or ACTIVE W. The primary outcomes of these studies are composites of vascular events. A total of 14000 patients will be enrolled in these trials. CONCLUSIONS: ACTIVE is the largest trial yet conducted in AF. Its results will lead to a new understanding of the role of combined antiplatelet therapy and the role of blood pressure lowering with an angiotensin II receptor blocker in patients with AF.
|
|
| 4. |
- Dawson, K. S., et al.
(author)
-
An Intensive Hubble Space Telescope Survey for z>1 Type Ia Supernovae by Targeting Galaxy Clusters
- 2009
-
In: Astronomical Journal. - : American Astronomical Society. - 0004-6256 .- 1538-3881. ; 138, s. 1271-1283
-
Journal article (peer-reviewed)abstract
- We present a new survey strategy to discover and study high-redshift Type Ia supernovae (SNe Ia) using the Hubble Space Telescope (HST). By targeting massive galaxy clusters at 0.9 < z < 1.5, we obtain a twofold improvement in the efficiency of finding SNe compared to an HST field survey and a factor of 3 improvement in the total yield of SN detections in relatively dust-free red-sequence galaxies. In total, sixteen SNe were discovered at z>0.95, nine of which were in galaxy clusters. This strategy provides an SN sample that can be used to decouple the effects of host-galaxy extinction and intrinsic color in high-redshift SNe, thereby reducing one of the largest systematic uncertainties in SN cosmology. Based on observations made with the NASA/ESA Hubble Space Telescope and obtained from the data archive at the Space Telescope Institute. STScI is operated by the Association of Universities for Research in Astronomy, Inc. under the NASA contract NAS 5-26555. The observations are associated with program 10496.
|
|
| 5. |
- Barbary, K., et al.
(author)
-
Discovery of an Unusual Optical Transient with the Hubble Space Telescope
- 2009
-
In: Astrophysical Journal. - 0004-637X .- 1538-4357. ; 690, s. 1358-1362
-
Journal article (peer-reviewed)abstract
- We present observations of SCP 06F6, an unusual optical transient discovered during the Hubble Space Telescope Cluster Supernova Survey. The transient brightened over a period of ~100 days, reached a peak magnitude of ~ 21.0 in both i 775 and z 850, and then declined over a similar timescale. There is no host galaxy or progenitor star detected at the location of the transient to a 3σ upper limit of i 775 >= 26.4 and z 850 >= 26.1, giving a corresponding lower limit on the flux increase of a factor of ~ 120. Multiple spectra show five broad absorption bands between 4100 Å and 6500 Å, and a mostly featureless continuum longward of 6500 Å. The shape of the light curve is inconsistent with microlensing. The transient's spectrum, in addition to being inconsistent with all known supernova types, does not match any spectrum in the Sloan Digital Sky Survey database. We suggest that the transient may be one of a new class. Based in part on observations made with the NASA/ESA Hubble Space Telescope, obtained from the data archive at the Space Telescope Science Institute (STScI). STScI is operated by the Association of Universities for Research in Astronomy (AURA), Inc. under the NASA contract NAS 5-26555. The observations are associated with program GO-10496. Based in part on observations obtained at the European Southern Observatory under ESO program 077.A-0110. Based in part on observations collected at Subaru Telescope, which is operated by the National Astronomical Observatory of Japan. Some of the data presented herein were obtained at the W.M. Keck Observatory, which is operated as a scientific partnership among the California Institute of Technology, the University of California, and NASA.
|
|
| 6. |
- Huang, X., et al.
(author)
-
HUBBLE SPACE TELESCOPE DISCOVERY OF A z=3.9 MULTIPLY IMAGED GALAXY BEHIND THE COMPLEX CLUSTER LENS WARPS J1415.1+36 AT z=1.026
- 2009
-
In: ASTROPHYS J LETT. ; 707:1, s. l12-L16
-
Journal article (peer-reviewed)abstract
- We report the discovery of a multiply lensed Ly alpha emitter at z = 3.90 behind the massive cluster WARPS J1415.1+3612 at z = 1.026. Images taken by the Hubble Space Telescope using the Advanced Camera for Surveys reveal a complex lensing system that produces a prominent, highly magnified arc and a triplet of smaller arcs grouped tightly around a spectroscopically confirmed cluster member. Spectroscopic observations using the Faint Object Camera and Spectrograph on Subaru confirm strong Lya emission in the source galaxy and provide the redshifts for more than 21 cluster members with a velocity dispersion of 807 +/- 185 km s(-1). Assuming a singular isothermal sphere profile, the mass within the Einstein ring (7.13 +/- 0.'' 38) corresponds to a central velocity dispersion of 686(-19)(+15) km s(-1) for the cluster, consistent with the value estimated from cluster member redshifts. Our mass profile estimate from combining strong lensing and dynamical analyses is in good agreement with both X-ray and weak lensing results.
|
|
| 7. |
|
|
| 8. |
- Rubin, D., et al.
(author)
-
Looking Beyond Lambda with the Union Supernova Compilation
- 2009
-
In: Astrophysical Journal. - 0004-637X .- 1538-4357. ; 695, s. 391-403
-
Journal article (peer-reviewed)abstract
- The recent robust and homogeneous analysis of the world's supernova distance-redshift data, together with cosmic microwave background and baryon acoustic oscillation data—provides a powerful tool for constraining cosmological models. Here we examine particular classes of scalar field, modified gravity, and phenomenological models to assess whether they are consistent with observations even when their behavior deviates from the cosmological constant Λ. Some models have tension with the data, while others survive only by approaching the cosmological constant, and a couple are statistically favored over Λ cold dark matter. Dark energy described by two equation-of-state parameters has considerable phase space to avoid Λ and next-generation data will be required to constrain such physics, with the level of complementarity between probes varying with cosmology.
|
|
| 9. |
- Connolly, John, et al.
(author)
-
Using MODIS derived fPAR with ground based flux tower measurements to derive the light use efficiency for two Canadian peatlands
- 2009
-
In: Biogeosciences. - : Copernicus GmbH. - 1726-4189. ; 32:6, s. 225-225
-
Journal article (peer-reviewed)abstract
- We used satellite remote sensing data; fractionof photosynthetically active radiation absorbed by vegetation(fPAR) from the Moderate Resolution Imaging Spectrora-diometer (MODIS) in combination with tower eddy covari-ance and meteorological measurements to characterise theLight Use Efficiency parameter (ε)variability and the maxi-mumε(εmax)for two contrasting Canadian peatlands. Eight-day MODISfPAR data were acquired for the Mer Bleue(2000 to 2003) and Western Peatland (2004). Flux towereddy covariance and meteorological measurements were in-tegrated to the same eight-day time stamps as the MODISfPAR data. A light use efficiency model: GPP =ε×APAR(where GPP is Gross Primary Productivity and APAR is ab-sorbed photosynthetically active radiation) was used to cal-culateε. Theεmaxvalue for each year (2000 to 2003) at theMer Bleue bog ranged from 0.58 g C MJ−1to 0.78 g C MJ−1and was 0.91 g C MJ−1in 2004, for the Western Peatland.The average growing seasonεfor the Mer Bleue bog forthe four year period was 0.35 g C MJ−1and for the West-ern Peatland in 2004 was 0.57 g C MJ−1. The average snowfree period for the Mer Bleue bog over the four years was 0.27 g C MJ−1and for the Western Peatland in 2004 was0.39 g C MJ−1. Using the light use efficiency method wecalculated theεmaxand the annual variability inεfor twoCanadian peatlands. We determined that temperature was agrowth-limiting factor at both sites Vapour Pressure Deficit(VPD) however was not. MODISfPAR is a useful tool forthe characterization ofεat flux tower sites.
|
|
| 10. |
- Connolly, Stuart J., et al.
(author)
-
Dabigatran versus warfarin in patients with atrial fibrillation
- 2009
-
In: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 361:12, s. 1139-1151
-
Journal article (peer-reviewed)abstract
- BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. METHODS: In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism. RESULTS: Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P<0.001 for superiority). The rate of major bleeding was 3.36% per year in the warfarin group, as compared with 2.71% per year in the group receiving 110 mg of dabigatran (P=0.003) and 3.11% per year in the group receiving 150 mg of dabigatran (P=0.31). The rate of hemorrhagic stroke was 0.38% per year in the warfarin group, as compared with 0.12% per year with 110 mg of dabigatran (P<0.001) and 0.10% per year with 150 mg of dabigatran (P<0.001). The mortality rate was 4.13% per year in the warfarin group, as compared with 3.75% per year with 110 mg of dabigatran (P=0.13) and 3.64% per year with 150 mg of dabigatran (P=0.051). CONCLUSIONS: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.)
|
|
